Disease-modifying trials in Alzheimer's disease: a European task force consensus.
about
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsMild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseCurrent and future uses of neuroimaging for cognitively impaired patients.Parallel imaging: is GRAPPA a useful acquisition tool for MR imaging intended for volumetric brain analysis?Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals.Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma.Developing a Dementia Research Registry: a descriptive case study from North Thames DeNDRoN and the EVIDEM programme.Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations.Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future.Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Multidisciplinary team meetings (MDTM) in detection of Alzheimer's disease: data from the IDEM study.Current and future treatments for Alzheimer's diseaseBridging molecular genetics and biomarkers in lewy body and related disordersFor debate: substituting placebo controls in long-term Alzheimer's prevention trials.The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration.Current Alzheimer's disease clinical trials: methods and placebo outcomes.Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).Test-retest reliability of a new medial temporal atrophy morphological metric.Studying micro RNA Function and Dysfunction in Alzheimer's DiseasePrediction of cognitive decline by positron emission tomography of brain amyloid and tau.Present and prospective clinical therapeutic regimens for Alzheimer's disease.Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.Current and future therapy in Alzheimer's disease.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology.New treatment strategies for Alzheimer's disease: is there a hope?Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.Vitamin B12 intake and status and cognitive function in elderly people.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial.Souvenaid®: a new approach to management of early Alzheimer's disease.The impact of protein supplementation on cognitive performance in frail elderly.Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis.
P2860
Q26866006-CF2CE9B0-50A0-4CB9-BAE0-2A80798F16DAQ27027319-BC0A9A24-602C-459F-8B0A-26A862EE0B96Q31143267-29DD3ECD-F860-4202-B6F4-973BFB6114C0Q33489842-45093E9C-6558-4820-8E86-17B4DC2BD8F8Q33496593-DFEB791D-E2CD-47C6-B996-64BB901BD1EAQ33575523-F8DC59A3-1F87-419B-B3EE-9EE4F23DA15DQ33805346-F8682FA4-968A-4A8F-B76A-D620A0D91DDEQ33852962-01F75B8A-9927-4070-AB31-4E156A91E95FQ34077895-C884AD58-43D8-4B7D-9512-D20DA5EEF05FQ34088600-52F9887D-7BA6-4D6A-B11C-E2682B725FD4Q34408888-5FAC8306-8AFA-4117-AAAE-27820E9DD2A2Q34567875-9160E683-554C-47EC-B9C1-28888B14D6E9Q34646921-9E5BB04C-5549-4229-B225-883974C8FCE5Q35094391-2B78EBE1-5579-4071-88BA-BDD8642C6DDAQ35579221-70F921A0-6FAE-4360-AF53-738B3369351EQ35833343-EC935447-10FB-4359-B441-8F0CCA09FCADQ35876532-208788D2-AC5B-4064-BB95-C3FEF44E5302Q36103515-DFF1D27F-9681-4D8F-A537-DAFE9B1BC709Q36277794-1CE623D7-6268-4920-B789-A5D30994B8C5Q36589571-90EC3554-0D53-4257-9437-73CC356366C1Q36759184-AA6CCA81-F3C8-498B-8F2F-D28D2B89E3ACQ36876447-ED1D2506-BCF8-477B-8CBE-02B87C7C47B5Q37044224-9978BE64-C45A-4CE1-AB02-5D288FAADDA3Q37165703-6981A5C7-F665-4E3B-A506-FE2DBDF7B1E6Q37198579-8A20CC89-8101-48A7-95BC-F7D3251BC892Q37203313-6F1D0A6D-CA79-4962-9A80-BE5B2F936DB4Q37403383-DE0870A8-6895-43D2-94B0-D0158D4C6FFBQ37600876-36F8EB74-2EE6-4393-9D8F-5340357E9B5BQ38037156-D27BF59F-3728-48F5-92C7-9B8ED8D2CF73Q38065812-BCE17198-5F83-4E03-ABB6-24ECAA6716CEQ38286222-457AEF37-C693-4017-9620-547B38D17A88Q38289739-1DB0143B-CACE-4215-9BBF-619024D24B97Q38832928-FA421526-3412-484E-B752-FD3EF833D083Q39571071-612D042C-F617-4F20-B897-58BB85C7CADCQ39780949-60060CBD-98A3-4FC7-8A8A-858B08F803C0Q43489430-A0A920EC-1645-43BA-9D00-BFF1F1A8735CQ43737116-EACFAAF2-5552-4871-B3A0-662095FB2235Q43864462-9BEE6C49-5191-4223-8956-D55CC0B00A2CQ45133524-6E6D875F-FA0A-4293-8453-B64C5E5EB8D1Q46050990-F18F4C27-1D84-4DAC-B2DF-6E59AB9E922A
P2860
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@ast
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@en
type
label
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@ast
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@en
prefLabel
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@ast
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@en
P2093
P1433
P1476
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
@en
P2093
European Task Force group
Gordon Wilcock
Sandrine Andrieu
P356
10.1016/S1474-4422(06)70677-9
P577
2007-01-01T00:00:00Z